Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.16
  • Today's Change-0.04 / -0.65%
  • Shares traded2.27m
  • 1 Year change-18.09%
  • Beta0.8556
Data delayed at least 15 minutes, as of Jul 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

  • Revenue in HKD (TTM)8.44bn
  • Net income in HKD1.67bn
  • Incorporated2006
  • Employees5.41k
  • Location
    3SBio IncNo. 3 A1, Road 10Shenyang Economy & TechnologyDevelopment ZoneSHENYANG 110027ChinaCHN
  • Phone+86 2 425811820
  • Fax+86 2 425811821
  • Websitehttps://www.3sbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AIM Vaccine Co Ltd1.28bn-1.40bn7.76bn1.62k--1.97--6.06-1.16-1.161.063.25------789,384.00--------75.88---164.24--0.7583-14.040.3158---6.06---307.07------
Yichang Hec Changjiang Pharmactcl Co Ltd6.80bn2.15bn8.07bn4.62k3.750.94193.331.192.442.447.729.740.51113.624.091,471,518.0015.078.0324.4611.8179.2179.9729.4820.801.3011.160.247515.8168.0820.182,501.2416.15-11.50--
Luye Pharma Group Ltd6.63bn574.99m10.42bn5.27k18.030.77027.781.570.15360.15361.783.600.2472.423.601,258,427.002.172.803.564.4568.4470.538.7810.391.213.100.393111.822.703.50-11.94-16.39-14.05--
Shanghai Henlius Biotech Inc5.82bn589.47m12.20bn3.64k20.765.1612.492.091.081.0810.674.350.57311.959.101,601,376.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.480.6512--67.82273.51178.53--49.14--
SSY Group Ltd6.46bn1.32bn12.77bn5.60k9.711.847.301.980.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Simcere Pharmaceutical Group Ltd7.13bn771.64m13.66bn7.03k18.551.8012.361.910.28950.28952.732.980.61063.532.651,015,172.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
Zai Lab Ltd2.27bn-2.65bn14.60bn2.18k--2.40--6.43-2.73-2.732.346.110.26972.845.61---31.41-37.72-36.81-42.7262.8664.75-116.45-282.444.43--0.0596--24.03360.0324.51---3.45--
3SBio Inc8.44bn1.67bn14.76bn5.41k9.140.97527.121.750.67410.67413.466.320.34261.587.011,559,395.006.957.449.039.2984.9882.9120.3021.502.2622.720.2266--13.8411.26-19.133.948.78--
China Medical System Holdings Ltd8.65bn2.59bn15.64bn5.70k6.060.9385.541.811.061.063.536.830.45173.426.191,517,442.0013.4418.4415.7021.1476.2475.4729.7634.263.98--0.077240.14-12.438.08-26.335.3538.695.19
Grand Pharmaceutical Group Ltd10.53bn1.88bn15.80bn10.53k8.311.036.901.500.53560.53563.004.330.46922.9410.26999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981922.960.183126.9410.1212.06-9.5921.415.6924.77
The United Laboratories Intl. Hldgs Ltd.14.83bn2.92bn16.06bn15.00k5.511.174.551.081.601.608.167.570.68713.366.15988,881.1013.517.8920.5212.6446.1144.1719.6612.731.74--0.105528.9921.2212.8470.8531.6624.1946.04
China Traditional Chinese Med Hldg CoLtd19.56bn1.39bn16.87bn17.30k12.160.73856.250.86230.27550.27553.884.540.49851.472.161,130,665.003.844.605.857.0751.1857.077.709.771.489.830.177317.3526.699.9968.11-2.24-12.75--
WuXi XDC Cayman Inc2.29bn306.10m17.40bn1.18k51.902.9547.037.590.27980.27982.134.92------1,946,385.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
Data as of Jul 26 2024. Currency figures normalised to 3SBio Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

9.81%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jul 202468.21m2.82%
Dimensional Fund Advisors LPas of 04 Jul 202436.77m1.52%
Bankinter Gesti�n de Activos SA SGIICas of 30 Jun 202326.52m1.10%
GF Fund Management Co., Ltd.as of 31 Dec 202325.74m1.07%
BlackRock Fund Advisorsas of 27 Jun 202421.06m0.87%
Norges Bank Investment Managementas of 31 Dec 202315.86m0.66%
Bosera Asset Management Co., Ltd.as of 31 Dec 202213.31m0.55%
BlackRock (Netherlands) BVas of 27 Jun 202410.72m0.44%
Ninety One UK Ltd.as of 29 Feb 20249.49m0.39%
BlackRock Investment Management (UK) Ltd.as of 27 Jun 20249.41m0.39%
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.